Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Trea...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2021-08-01
|
| Edice: | Medicina |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/1648-9144/57/9/857 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|